Shirazi M, Haghpanah A R, Badiee M, Afrasiabi M A, Haghpanah S
Department of Urology, Shahid Faghihi Hospital, Shiraz University of Medical Science, Shiraz, Iran.
Int Urol Nephrol. 2009;41(3):467-71. doi: 10.1007/s11255-009-9522-4. Epub 2009 Feb 6.
We aimed to assess the effect of intralesional verapamil on the treatment of Peyronie's disease.
This randomized study involved 80 patients. First, they were divided into two groups. The first group (case: 40 patients) received intralesional verapamil and the second group (control: 40 patients) local saline injection. They were followed about 24 weeks and evaluated for the size of plaques, plaque softening, reduction of pain and amelioration of penile deformity and erectile dysfunction (estimated by the International Index of Erectile Function) before and after treatment.
Reduction of plaque size was seen in 17.5% of the case group and 12.8% of the control group (P: 0.755). Pain was reduced in 30% of the case group and 28.2% of the control group (P: 0.99). Curvature was decreased in 17.5% of the case group and 23.1% the control group (P: 0.586). Plaque softening was seen in 30% of the case group compared with 25.6% improvement in the control group (P: 0.803). Also we found 5% and 2.6% improvement in sexual dysfunction in the case and control groups, respectively. (P: 0.985).
Although in some studies verapamil has been found to be effective in the treatment of Peyronie's disease, we did not find any improvement in comparison with the control group. Furthermore, larger scale studies are warranted to assess the effect of this drug on the treatment of Peyronie's disease.
我们旨在评估病灶内注射维拉帕米对佩罗尼氏病的治疗效果。
这项随机研究纳入了80例患者。首先，将他们分为两组。第一组（病例组：40例患者）接受病灶内注射维拉帕米，第二组（对照组：40例患者）接受局部注射生理盐水。对他们进行了约24周的随访，并在治疗前后评估斑块大小、斑块软化情况、疼痛减轻程度、阴茎畸形改善情况以及勃起功能障碍（通过国际勃起功能指数评估）。
病例组中17.5%的患者斑块大小减小，对照组中这一比例为12.8%（P：0.755）。病例组中30%的患者疼痛减轻，对照组中这一比例为28.2%（P：0.99）。病例组中17.5%的患者弯曲度减小，对照组中这一比例为23.1%（P：0.586）。病例组中30%的患者出现斑块软化，对照组中改善比例为25.6%（P：0.803）。此外，我们发现病例组和对照组性功能障碍的改善率分别为5%和2.6%（P：0.985）。
尽管在一些研究中发现维拉帕米对佩罗尼氏病的治疗有效，但与对照组相比，我们未发现任何改善。此外，有必要进行更大规模的研究来评估这种药物对佩罗尼氏病的治疗效果。
